
IMU-935 is less effective than a placebo, Immunic shares plummet
On October 20, Immunic announced that its Phase Ib clinical trial of its RORγt inverse agonist IMU-935 in the treatment of psoriasis failed to meet
On October 20, Immunic announced that its Phase Ib clinical trial of its RORγt inverse agonist IMU-935 in the treatment of psoriasis failed to meet